Integrating HIV Prevention Gender-Affirmative Medical Care and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study
Brief description of study
This study is being done to learn whether
to provide HIV prevention services in conjunction with gender-affirming hormone
therapy for transgender women and assess the safety of this intervention in the
United States and Brazil.
All participants will be offered
medications to prevent HIV, known as Pre-exposure prophylaxis (PrEP). These
medications are called Descovy® and Truvada®. When used
every day, it most likely will help you to avoid becoming infected with HIV.
Detailed description of study
The HIV Prevention
Trials Network (HPTN) and Penn HIV
Prevention CRS are doing this study to learn how best to prevent
transgender women from acquiring HIV in the United States and Brazil.
Participants will be
given the opportunity to take medications to prevent HIV. The medication to
prevent becoming infected with HIV is sometimes called pre-exposure prophylaxis
or “PrEP.” PrEP is a way to prevent HIV infection for people who do not have
HIV (the virus that causes AIDS) by taking a pill every day. HIV is the virus
that causes Acquired Immunodeficiency Syndrome, or AIDS. The drugs being used
for PrEP in this study are called Descovy® and Truvada®.
Descovy® and Truvada® are pills that have two drugs in
them called “emtricitabine” and one of two forms of “tenofovir”. These
medicines are also used in combination with other medicines to treat HIV. You
and your study clinician will make a choice of which PrEP medicine is best for
you together.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
HIV
-
Age: Between 18 Years - 99 Years
-
Gender: Transgender
This study will enroll people
who were assigned male sex at birth and who currently identify themselves as
women, transgender women, or along a trans feminine spectrum, who are age 18
years or older, who are sexually active and who are HIV negative.
Updated on
28 Mar 2023.
Study ID: 844745
